![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Columbia MO (SPX) Feb 10, 2022
Due to a recent unexpected reactor shutdown in Europe, the University of Missouri Research Reactor (MURR) has increased its production of critical medical radioisotopes in an effort to help alleviate the anticipated disruption on the global supply chain. MURR is currently the sole producer of molybdenum-99 (Mo-99), iodine-133 (I-131), and lutetium-177 (Lu-177) in the United States, all of which are used for medical diagnoses or treatment of cancer and other disease. The European reactor is one of the main suppliers for these isotopes in Europe. With that reactor shut down, MU's facility is working to help meet the increase in demand internationally. Having shortages of these key radioisotopes can be a major issue for patients due to these drugs' short shelf lives, said J. David Robertson, the executive director of MURR. "An interruption in the supply of medical radioisotopes is a critical issue since, unlike typical drugs, these drugs cannot be stockpiled due to their short half-lives, or their quickly diminishing effectiveness as their active ingredients undergo radioactive decay," Robertson said. "This means if these drugs are not produced this week, cancer patients will not receive their treatments next week." Mo-99 is the "parent" of technetium-99m, the most widely used radioisotope for medical imaging. I-131 is highly effective in treating thyroid cancer, the most rapidly increasing cancer in the U.S. and the most common cancer in women ages 20 to 34. Lu-177 is a newer therapy approved by the FDA to treat neuroendocrine tumors (NETS) and has been shown in recent clinical trials to be effective in treating metastatic castrate-resistant prostate cancer. This is not the first time MURR has helped boost the international supply of radioisotopes. In early 2014, the facility postponed its regularly scheduled maintenance in order to stay online and maintain production during another international supply chain disruption. Robertson anticipates MURR also will maintain its increased production levels throughout the duration of the reactor shutdown in Europe, which is undetermined at this time. "MURR is fortunate to be in a position where we can increase our production when the global supply chain is impacted because we operate six and a half days a week, 52 weeks per year," Robertson said. "Our dedicated staff are committed to getting life-saving treatments delivered to the patients who need them." During 2017, the facility was relicensed by the Nuclear Regulatory Commission (NRC) for another 20 years of operation, and due to the reactor's novel design, individual components can be replaced as needed, effectively keeping the reactor's systems updated with the latest technology.
![]() ![]() Atlanta to host key SMR and Advanced Reactor event in May London, UK (SPX) Feb 10, 2022 Nuclear power's role in cutting carbon emissions will be a major topic at SMR and Advanced Reactor 2022 in Atlanta, Reuters Events announced today. The world's foremost event for advanced and small modular reactors (SMRs) will take place in the Georgia state capital on May 24 and 25, bringing together more than 500 experts together in a sector that could be key in the global fight against climate change. Confirmed speakers include Nuclear Energy Institute Chief Executive Officer Maria Korsni ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |